NCT01649271 2025-02-11Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.Boehringer IngelheimPhase 1 Completed13 enrolled 11 charts
NCT01522768 2023-11-01Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric CancerMemorial Sloan Kettering Cancer CenterPhase 2 Completed42 enrolled 9 charts